ATHX Athersys Inc

EDISON EQUITY RESEARCH: ATHERSYS - ONE DOOR CLOSES, ANOTHER ONE OPENS

Today, Athersys announced that the agreement between the company and Chugai to develop and commercialize MultiStem in Japan has ended following the failure of negotiations to modify the financial terms of the agreement and to decide on a development strategy. However, Athersys also announced that it has already signed a letter of intent with another Japanese company to develop and commercialize MultiStem in Japan in ischemic stroke and other areas.

Athersys is a US biotech company developing MultiStem (allogeneic, bone marrow-derived stem cells). A Phase II trial with MultiStem in ischemic stroke has completed, while further studies in AMI (Phase II) and ARDS (Phase IIa) are planned.

To view our full report, please click here

Click here to view all of Edison Investment Research’s published reports